Protagenic Therapeutics Net Income
| PTIX Stock | USD 0.40 0.09 18.37% |
As of the 7th of February, Protagenic Therapeutics holds the Variance of 112.77, risk adjusted performance of (0.16), and Coefficient Of Variation of (486.81). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Protagenic Therapeutics, as well as the relationship between them.
Protagenic Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Protagenic Therapeutics' valuation are provided below:We have found one hundred twenty available trending fundamental ratios for Protagenic Therapeutics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Protagenic Therapeutics recent market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -5 M | -5.2 M | |
| Net Loss | -5 M | -4.7 M | |
| Net Loss | -4.1 M | -3.9 M | |
| Net Loss | (1.01) | (1.07) | |
| Net Income Per E B T | 0.90 | 0.78 |
Protagenic | Net Income | Build AI portfolio with Protagenic Stock |
The evolution of Net Income for Protagenic Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Protagenic Therapeutics compares to historical norms and industry peers.
Latest Protagenic Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Protagenic Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Protagenic Therapeutics financial statement analysis. It represents the amount of money remaining after all of Protagenic Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Protagenic Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (5.53 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Protagenic Net Income Regression Statistics
| Arithmetic Mean | (2,635,551) | |
| Coefficient Of Variation | (69.05) | |
| Mean Deviation | 1,527,567 | |
| Median | (2,276,000) | |
| Standard Deviation | 1,819,790 | |
| Sample Variance | 3.3T | |
| Range | 5M | |
| R-Value | (0.94) | |
| Mean Square Error | 415.5B | |
| R-Squared | 0.88 | |
| Slope | (338,517) | |
| Total Sum of Squares | 53T |
Protagenic Net Income History
Other Fundumenentals of Protagenic Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Protagenic Therapeutics Net Income component correlations
Protagenic Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Protagenic Therapeutics is extremely important. It helps to project a fair market value of Protagenic Stock properly, considering its historical fundamentals such as Net Income. Since Protagenic Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protagenic Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protagenic Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. Anticipated expansion of Protagenic directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Protagenic Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Protagenic Therapeutics's market price often diverges from its book value, the accounting figure shown on Protagenic's balance sheet. Smart investors calculate Protagenic Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Protagenic Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Protagenic Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Protagenic Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Protagenic Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Protagenic Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Protagenic Therapeutics.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Protagenic Therapeutics on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Protagenic Therapeutics or generate 0.0% return on investment in Protagenic Therapeutics over 90 days. Protagenic Therapeutics is related to or competes with Lipella Pharmaceuticals, Artelo Biosciences, Indaptus Therapeutics, Biomotion Sciences, Revelation Biosciences, Scisparc, and GT Biopharma. Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to ... More
Protagenic Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Protagenic Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Protagenic Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 58.73 | |||
| Value At Risk | (18.37) | |||
| Potential Upside | 14.81 |
Protagenic Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagenic Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Protagenic Therapeutics' standard deviation. In reality, there are many statistical measures that can use Protagenic Therapeutics historical prices to predict the future Protagenic Therapeutics' volatility.| Risk Adjusted Performance | (0.16) | |||
| Jensen Alpha | (1.96) | |||
| Total Risk Alpha | (3.24) | |||
| Treynor Ratio | 0.7595 |
Protagenic Therapeutics February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.16) | |||
| Market Risk Adjusted Performance | 0.7695 | |||
| Mean Deviation | 7.17 | |||
| Coefficient Of Variation | (486.81) | |||
| Standard Deviation | 10.62 | |||
| Variance | 112.77 | |||
| Information Ratio | (0.21) | |||
| Jensen Alpha | (1.96) | |||
| Total Risk Alpha | (3.24) | |||
| Treynor Ratio | 0.7595 | |||
| Maximum Drawdown | 58.73 | |||
| Value At Risk | (18.37) | |||
| Potential Upside | 14.81 | |||
| Skewness | (0.12) | |||
| Kurtosis | 4.4 |
Protagenic Therapeutics Backtested Returns
Protagenic Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.17, which implies the firm had a -0.17 % return per unit of risk over the last 3 months. Protagenic Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Protagenic Therapeutics' Variance of 112.77, coefficient of variation of (486.81), and Risk Adjusted Performance of (0.16) to confirm the risk estimate we provide. The company holds a Beta of -2.89, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Protagenic Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Protagenic Therapeutics is expected to outperform it. At this point, Protagenic Therapeutics has a negative expected return of -1.88%. Please make sure to check Protagenic Therapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Protagenic Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.42 |
Average predictability
Protagenic Therapeutics has average predictability. Overlapping area represents the amount of predictability between Protagenic Therapeutics time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Protagenic Therapeutics price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Protagenic Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.57 | |
| Residual Average | 0.0 | |
| Price Variance | 0.09 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Protagenic Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Protagenic Therapeutics reported net income of (5.53 Million). This is 101.62% lower than that of the Biotechnology sector and 107.89% lower than that of the Health Care industry. The net income for all United States stocks is 100.97% higher than that of the company.
Protagenic Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protagenic Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protagenic Therapeutics could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics of similar companies.Protagenic Therapeutics is currently under evaluation in net income category among its peers.
Protagenic Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Protagenic Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Protagenic Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Protagenic Therapeutics' value.| Shares | Geode Capital Management, Llc | 2025-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 18.8 K | Alpine Partners Vi, Llc | 2025-06-30 | 16.4 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 15 K | Susquehanna International Group, Llp | 2025-06-30 | 10.2 K | Ubs Group Ag | 2025-06-30 | 9 K | Tower Research Capital Llc | 2025-06-30 | 876 | Citigroup Inc | 2025-06-30 | 390 | Bank Of America Corp | 2025-06-30 | 6.0 | Harbor Investment Advisory, Llc | 2025-06-30 | 1.0 |
Protagenic Fundamentals
| Return On Equity | -5.13 | ||||
| Return On Asset | -1.9 | ||||
| Current Valuation | 2.22 M | ||||
| Shares Outstanding | 1.93 M | ||||
| Shares Owned By Insiders | 3.59 % | ||||
| Shares Owned By Institutions | 6.46 % | ||||
| Number Of Shares Shorted | 61.71 K | ||||
| Price To Earning | 9.43 X | ||||
| Price To Book | 1.61 X | ||||
| EBITDA | (5.47 M) | ||||
| Net Income | (5.53 M) | ||||
| Cash And Equivalents | 8.87 M | ||||
| Cash Per Share | 0.51 X | ||||
| Total Debt | 942.76 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 19.47 X | ||||
| Book Value Per Share | (2.43) X | ||||
| Cash Flow From Operations | (4.22 M) | ||||
| Short Ratio | 0.56 X | ||||
| Earnings Per Share | (13.13) X | ||||
| Target Price | 4.0 | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 776.94 K | ||||
| Total Asset | 1.96 M | ||||
| Retained Earnings | (36.3 M) | ||||
| Working Capital | 940.11 K | ||||
| Current Asset | 3.75 M | ||||
| Current Liabilities | 736 K | ||||
| Net Asset | 1.96 M |
About Protagenic Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protagenic Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protagenic Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protagenic Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.